Snapshots of the fluorosalinosporamide/20S complex offer mechanistic insights for fine tuning proteasome inhibition

Journal of Medicinal Chemistry

Volumn 52, Issue 17, 2009, Pages 5420-5428

  Groll, Michael ^a   McArthur, Katherine A ^b   Macherla, Venkat R ^b   Manam, Rama Rao ^b   Potts, Barbara C ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Nereus Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

20S PROTEASOME; BIOLOGICAL RESPONSE MODIFIER; BROMOSALINOSPORAMIDE 20S PROTEASOME COMPLEX; FLUORINE; FLUOROSALINOSPORAMIDE 20S PROTEASOME COMPLEX; HYDROXYSALINOSPORAMIDE 20S PROTEASOME COMPLEX; PROTEASOME; PROTEASOME INHIBITOR; SALINOSPORAMIDE A; UNCLASSIFIED DRUG;

ARTICLE; CRYSTAL STRUCTURE; DRUG ACTIVITY; DRUG MECHANISM; INHIBITION KINETICS; LIGAND BINDING; PROTEIN STABILITY; STRUCTURE ACTIVITY RELATION; YEAST;

BROMIDES; BUFFERS; CRYSTALLOGRAPHY, X-RAY; ENZYME INHIBITORS; HYDROCARBONS, FLUORINATED; HYDROGEN-ION CONCENTRATION; LACTONES; LIGANDS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PROTEASOME ENDOPEPTIDASE COMPLEX; SACCHAROMYCES CEREVISIAE; WATER;

EID: 69949108710     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm900559x     Document Type: Article

References (45)

1. Adams, J. Proteasome Inhibitors in Cancer Therapy; Humana Press: Totowa, NJ, 2004.
2. Orlowski, R. Z.; Kuhn, D. J. Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade. Clin. Cancer Res. 2008, 14, 1649-1657.
3. Bross, P. F.; Kane, R.; Farrell, A. T.; Abraham, S.; Benson, K.; Brower, M. E.; Bradley, S.; Gobburu, J. V.; Goheer, A.; Lee, S.-L.; Leighton, J.; Liang, C. Y.; Lostritto, R. T.; McGuinn, W. D.; Morse, D. E.; Rahman, A.; Rosario, L. A.; Verbois, S. L.; Williams, G.; Wang, Y.-C.; Pazdur, R. Approval Summary for Bortezomib for Injection in the Treatment of Multiple Myeloma. Clin. Cancer Res. 2004, 10, 3954-3964.
4. Richarson, P. G.; Barlogie, B.; Berenson, J.; Singhal, S.; Jagannath, S.; Irwin, D.; Rajkumar, S. V.; Srkalovic, G.; Alsina, M.; Alexanian, R.; Seigel, D.; Orlowski, R. Z.; Kuter, D.; Limentani, S. A.; Lee, S.; Hideshima, T.; Esseltine, D. L.; Kauffman, M.; Adams, J.; Schenkein, D. P.; Anderson, K. C. A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma. N. Engl. J. Med. 2003, 348, 2609-2617.
5. Groll, M.; Bochtler, M.; Brandstetter, H.; Clausen, T.; Huber, R. Molecular Machines for Protein Degradation. ChemBioChem 2005, 6, 222-256.
6. Lowe, J.; Stock, D.; Jap, B.; Zwickl, P.; Baumeister, W.; Huber, R. Crystal Structure of the 20S Proteasome from the Archaeon T. acidophilum at 2.4 A° Resolution. Science 1995, 268, 533-539.
7. Groll, M.; Ditzel, L.; Lowe, J.; Stock, D.; Bochtler, M.; Bartunik, H. D.; Huber, R. Structure of 20S Proteasome from Yeast at 2.4 A° Resolution. Nature 1997, 386, 463-471.
8. Groll, M.; Huber, R. Inhibitors of the Eukaryotic 20S Proteasome Core Particle: A Structural Approach. Biochim. Biophys. Acta 2004, 1695, 33-44.
9. Moore, B. S.; Eustaquio, A. S.; McGlinchey, R. P. Advances in and Applications of Proteasome Inhibitors. Curr. Opin. Chem. Biol. 2008, 12, 434-440.
10. Borissenko, L.; Groll, M. 20S Proteasome and Its Inhibitors: Crystallographic Knowledge for Drug Development. Chem. Rev. 2007, 107, 687-717.
11. Feling, R. H.; Buchanan, G. O.; Mincer, T. J.; Kauffman, C. A.; Jensen, P. R.; Fenical, W. Salinosporamide A: A Highly Cytotoxic Proteasome Inhibitor from a Novel Microbial Source, a Marine Bacterium of the New Genus Salinospora. Angew. Chem., Int. Ed. 2003, 42, 355-357.
12. Fenical, W.; Jensen, P. R.; Palladino, M. A.; Lam, K. S.; Lloyd, G. K.; Potts, B. C. Discovery and Development of the Anticancer Agent Salinosporamide A (NPI-0052). Bioorg. Med. Chem. 2009, 17, 2175-2180
13. Chauhan, D.; Catley, L.; Li, G.; Podar, K.; Hideshima, T.; Velankar, M.; Mitsiades, C.; Mitsiades, N; Yasui, H.; Letai, A.; Ovaa, H.; Berkers, C.; Nicholson, B.; Chao, T.-H.; Neuteboom, S. T. C.; Richardson, P.; Palladino, M. A.; Anderson, K. C. A Novel Orally Active Proteasome Inhibitor Induces Apoptosis in Multiple Myeloma Cells with Mechanisms Distinct from Bortezomib. Cancer Cell 2005, 8, 407-419. (Pubitemid 41579835)
14. Chauhan, D.; Hideshima, T.; Anderson, K. C. A Novel Proteasome Inhibitor NPI-0052 as an Anticancer Therapy. Br. J. Cancer 2006, 95, 961-965. (Pubitemid 44606819)
15. Cusack, J.; Liu, R.; Xia, L.; Pien, C.; Niu, W.; Palombella, V.; Chao, T-H.; Neuteboom, S. T. C.; Palladino, M. A. NPI-0052 Enhances Tumoricidal Response to Conventional Cancer Therapy in a Colon Cancer Model. Clin. Cancer Res. 2006, 12, 6758-6764.
16. Sloss, C. M.; Wang, F.; Liu, R.; Houston, M.; Ljungman, D.; Palladino, M. A.; Cusack, J. C. Proteasome Inhibition Activates Epidermal Growth Factor Receptor (EGFR) and EGFR-Independent Mitogenic Kinase Signaling Pathways in Pancreatic Cancer Cells. Clin. Cancer Res. 2008, 14, 5116-5123.
17. Aghajanian, C. A.; Hamlin, P.; Gordon, M. S.; Hong, D. S.; Naing, A.; Younes, A.; Hannah, A.; Palladino, M. A.; Spear, M. A.; Kurzrock, R. Phase I Study of the Novel Proteasome Inhibitor NPI-0052 in Patients with Lymphoma and Solid Tumors. J. Clin. Oncol., Suppl. 2008, 26 (15S, Part 1 of 2), 171S; Abstract 3574.
18. Padrik, P.; Price, T. J.; Spear, M. A.; Townsend, A.; Longenecker, A.; Palladino, M. A.; Lloyd, G. K.; Cropp, G. F.; Millward, M. Phase I Study of the Novel Proteasome Inhibitor NPI-0052 in Patients with Advanced Malignancies Including Leukemias. Ann. Oncol. 2008, 19 (Suppl. 8), viii162, 489P.
19. Manam, R. R.; McArthur, K. A.; Chao, T.-H.; Weiss, J.; Ali, J. A.; Palombella, V. J.; Groll, M.; Lloyd, G. K.; Palladino, M. A.; Neuteboom, S. T. C.; Macherla, V. R.; Potts, B. C. M. Leaving Groups Prolong the Duration of 20S Proteasome Inhibition and Enhance the Potency of Salinosporamides. J. Med. Chem. 2008, 51, 6711-6724.
20. Palladino, M. A.; Chao, T-H.; Neuteboom, S. T. C.; Spear, M.; Ma, W.; Albitar, M. Preclinical and Clinical Monitoring of Cell and Circulating Plasma Specific Proteasome Biomarkers after Treatment with the Proteasome Inhibitor NPI-0052. EJC Suppl. 2008, 6 (12), 74; Abstract 235 .
21. Macherla, V. R.; Mitchell, S. S.; Manam, R. R.; Reed, K.; Chao, T.-H.; Nicholson, B.; Deyanat-Yazdi, G.; Mai, B.; Jensen, P. R.; Fenical, W.; Neuteboom, S. T. C.; Lam, K. S.; Palladino, M. A.; Potts, B. C. M. Structure-Activity Relationship Studies of Salinosporamide A (NPI-0052), a Novel Marine Derived Proteasome Inhibitor. J. Med. Chem. 2005, 48, 3684-3687.
22. Groll, M.; Huber, R.; Potts, B. C. M. Crystal Structures of SalinosporamideA (NPI-0052) and B (NPI-0047) in Complex with the 20S Proteasome Reveal Important Consequences of β-Lactone Ring Opening and a Mechanism for Irreversible Binding. J. Am. Chem. Soc. 2006, 128, 5136-5141.
23. Bohm, H.-J.; Banner, D.; Bendels, S.; Kansy, M.; Kuhn, B.; Muller, K.; Obst-Sander, U.; Stahl, M. Fluorine in Medicinal Chemistry. ChemBioChem 2004, 5, 637-643.
24. Biffinger, J. C.; Kim, H. W.; DiMagno, S. G. The Polar Hydrophobicity of Fluorinated Compounds. ChemBioChem 2004, 5, 622-627.
25. Howard, J. A. K.; Hoy, V. J.; O'Hagen, D.; Smith, G. T. How Good Is Fluorine as a Hydrogen Bond Acceptor? Tetrahedron 1996, 38, 12613-12622.
26. Dunitz, J. D.; Taylor, R. Organic Fluorine Hardly Ever Accepts Hydrogen Bonds. Chem. Eur. J. 1997, 3, 89-98.
27. Eustaquio, A. S.; Moore, B. S. Mutasynthesis of Fluorosalinosporamide, a Potent and Reversible Inhibitor of the Proteasome. Angew. Chem., Int. Ed. 2008, 47, 3936-3938.
28. Seebach, D. Organic Synthesis. Where Now? Angew. Chem., Int. Ed. 1990, 29, 1320-1367.
29. 3 Carbon. Org. Lett. 2005, 7, 1271-1274.
30. Djuric, S. W.; Garland, R. B.; Nysted, L. N.; Pappo, R.; Plume, G.; Swenton, L. Synthesis of 5-Fluoroprostacyclin. J. Org. Chem. 1987, 52, 978-990.
31. Toscano, L.; Fioriello, G.; Silingardi, S.; Inglesi, M. Preparation of (8S)-8-Fluoroerythronolide A and (8S)-8-Fluoroerythronolide B, Potential Substrates for the Biological Synthesis of New Macrolide Antibiotics. Tetrahedron 1984, 40, 2177-2181.
32. 3LG Model System. Chem. Phys. Lett. 2006, 420, 95-99.
33. Brünger, A.; Adams, P.; Clore, G.; DeLano, W.; Gros, P.; Grosse- Kunstleve, R.; Jiang, J.; Kuszewski, J.; Nilges, M.; Pannu, N.; Read, R.; Rice, L.; Simonson, T.; Warren, G. Crystallography & NMR System: A New Software Suite for Macromolecular Structure Determination. Acta Crystallogr., Sect. D. 1998, 1, 905-921.
34. Turk, D. Improvement of a Program for Molecular Graphics and Manipulation of Electron Densities and Its Application for Protein Structure Determination. Thesis, Technische Universität München, Germany, 1992.
35. Groll, M.; Balskus, E. P.; Jacobsen, E. N. Structural Analysis of Spiro β-Lactone Proteasome Inhibitors. J. Am. Chem. Soc. 2008, 130, 14981-14983.
36. Denora, N.; Potts, B. C. M.; Stella, V. J.A Mechanistic and Kinetic Study of the β-Lactone Hydrolysis of Salinosporamide A (NPI- 0052), a Novel Proteasome Inhibitor. J. Pharm. Sci. 2007, 96, 2037-2047.
37. Potential contributions from the neighboring carboxylate anion are unknown.
38. Cassidy, C. S.; Lin, J.; Frey, P. A. A New Concept for the Mechanism of Action of Chymotrypsin: The Role of the Low-Barrier Hydrogen Bond. Biochemistry 1997, 36, 4576-4584.
39. Lin, J.; Cassidy, C. S.; Frey, P. A. Correlations of the Basicity of His 57 with Transition State Analogue Binding, Substrate Reactivity, and the Strength of the Low-Barrier Hydrogen Bond in Chymotrypsin. Biochemistry 1998, 37, 11940-11948.
40. Lin, J.; Westler, W. M.; Cleland, W. W.; Markley, J. L.; Frey, P. A. Fractionation Factors and Activation Energies for Exchange of the Low Barrier Hydrogen Bonding Proton in Peptidyl Trifluoromethyl Ketone Complexes of Chymotrypsin. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 14644-14668.
41. Tanford, C. The Interpretation of Hydrogen Ion Titration Curves of Proteins. Adv. Protein Chem. 1962, 17, 69-165.
42. Hale, R.; Miller, C.; Manam, R. R.; Macherla, V. R.; Palladino, M.; Potts, B.; Chandra, J. Analysis of Reactive Oxygen Species (ROS) Generation and Caspase-8 Activation by Analogs of Proteasome Inhibitor NPI-0052. In Proceedings of the 100th Annual Meeting of the American Association for Cancer Research, Denver, CO, Apr 18-22, 2009; AACR: Abstract 5634.
43. Reed, K. A.; Manam, R. R.; Mitchell, S. S.; Xu, J; Teisan, S.; Chao, T.-H.; Deyanat-Yazdi, G.; Neuteboom, S. T. C.; Lam, K. S.; Potts, B. C. M. Salinosporamides D-J from the Marine Actinomycete Salinispora tropica, Bromosalinosporamide, and Thioester Derivatives Are Potent Inhibitors of the 20S proteasome. J. Nat. Prod. 2007, 70, 269-276.
44. Groll, M.; Huber, R. Purification, Crystallization and X-ray Analysis of the Yeast 20S Proteasomes. Methods Enzymol. 2005, 398, 329-336. (Pubitemid 41578895)
45. Kabsch, W. Automatic Processing of Rotation Diffraction Data from Crystals of Initially Unknown Symmetry and Cell Constants. J. Appl. Crystallogr. 1993, 26, 795-800.